TABLE 1.

Reasons cited for the commercial challenges of Zevalin and Bexxar, highlighting market-driven forces that contributed to declining sales and discontinuation of the drugs.

	Zevalin	Bexxar
Preference for familiar tools and processes amongst physicians	X	X
Complicated prescribing, administration, and monitoring process	X	X
Complicated referral/referral outside of doctors’ offices	X	X
Complex dosimetry requirements	X	X
Unclear data around long-term benefit/outcomes	X	X
Potential toxicities	X	X
High price/costs	X	X
Reimbursement challenges	X	X
Clinical trial strategy challenges/delays with FDA		X
Manufacturing and supply-chain challenges	X	X
Public fears about radiation risks	X	X

Note that Zevalin is still marketed for use in Europe.